Medivir entered into an agreement with Karo Pharma to sell its subsidiary BioPhausia
Medivir is set to sell is subsidiary, BioPhausia, to Karo Pharmafor for Skr908m ($100.9m). The agreement shows that this price will be on a cash and debt free basis, including a normalized working capital, with the transaction expected to close by mid-December. BioPhausia comprises 13 established pharmaceutical drugs. From the third quarter of 2015 to the second quarter of 2016, BioPhausia posted revenues of Skr189m ($21m).
Astellas to acquire German company Ganymed Pharmaceuticals
Japan’s Astellas Pharma has signed an agreement to acquire German-based biopharmaceutical company Ganyme...
